echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > 2020 EHA . . . China's CLL1-CD33 dual-target compound CAR-T was selected best-of-the-Theme, excellent efficacy. The doctor was bombarded with explosives.

    2020 EHA . . . China's CLL1-CD33 dual-target compound CAR-T was selected best-of-the-Theme, excellent efficacy. The doctor was bombarded with explosives.

    • Last Update: 2020-07-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Nearly 100 authoritative leaders of domestic bio innovative drugs have spoken, hundreds of leading Biopharmaceutical Enterprises have paid close attention to it. More than 1000 pharmaceutical peers have signed up to participate. Dozens of innovative drug technologies have been collectively unveiled. Four hot biomedical fields, including tumor immunity, new antibodies, stem cell regenerative medicine, and gene therapy, are focused on. 2020 bpit The biopharmaceutical innovation technology conference will be held in Nanjing International Youth Cultural Center. From July 19 to 21, 2020, we will pay tribute to the next golden decade of innovative drugs and witness the new goals and new mileage of Chinese innovative drugs! This article is originally created by emaker, welcome to share, and reprinted with authorization. July 6, 2020 / emedclub news / - - European Blood Association (EHA) was established in 1992. It is a non-profit organization dedicated to promoting clinical practice, research and education of Hematology. It is one of the largest independent providers of hematology knowledge in the world.

    recently, the 25th EHA meeting in 2020 has been held in the form of virtual meeting, and two studies in China have been included in the 'best of theme' acute leukemia section.

    they are the clinical study of cll1-cd33 dual target car-t therapy (icg144), which was developed by Professor Liu Fang, director of hematopoietic stem cell transplantation center of Western Theater General Hospital (former Chengdu Military Region General Hospital), and another genhi biological targeted CD7 treatment for relapsed or refractory acute T-cell leukemia (R / R) Clinical study of gc027, a kind of car-t cell therapy for T-ALL.

    for a long time, specific car-t cell therapy targeting CD19 has achieved good results in patients with acute lymphoblastic leukemia.

    however, due to the heterogeneity of acute myeloid leukemia (AML), the treatment of AML patients is still a challenge, which makes car-t cell therapy targeting single antigen ineffective.

    and Dr. Liu Fang's icg144 trial is the first clinical trial of "cll1-cd33" dual target compound car-t in patients with relapsed / refractory acute myeloid leukemia (AML).

    } mechanism of action of car-t complex (photo source: bloodwise) the new car-t therapy of "cll1-cd33" uses double targets and targets cll1 and CD33 receptors highly expressed on the surface of acute myeloid leukemia (AML).

    principle: (1) cll1 receptor targets leukemia stem cells (this kind of cells are a small subset of slow growing leukemia cells, which can resist conventional drug treatment and stably proliferate into new leukemia cell branches).

    cll1 is associated with leukemia stem cells and disease recurrence. (2) CD33 receptor targets most AML cells.

    } target antigen is a key factor in car-t cell therapy. As early as December 2017, Dr. Liu Fang, the author of the study, adopted the dual target car-t therapy to save the life of a child with AML; after that, Dr. Liu Fang launched long-term research and clinical trials on this therapy.





    in June 2018, Dr. Liu Fang demonstrated the experimental results of cll1-cd33 composite car (CCAR) in mice at the 23rd EHA, proving that ccar-t cells have strong anti-tumor activity; in December 2018, Dr. Liu Fang published the first clinical study data of this therapy on ash, and published the latest clinical trial data of grade 1 dose increase in patients with relapsed / refractory AML CCAR T cells showed consistent, specific and effective antitumor activity in vitro and in vivo.

    at the 25th EHA meeting, Dr. Liu Fang released the latest clinical progress data of this therapy (as shown in the figure).

    at present, 9 patients with cll1-cd33 car-t cell therapy have been completed in this study. The patients' ages ranged from 6 to 48 years old. Except one patient, the myeloid leukemia cells in the other 8 patients expressed CD33 and cll1 receptors at the same time.

    after treatment, 7 out of 9 patients achieved complete remission (CR), i.e. no cancer cells were detected in vivo.

    } clinical trial data of cll1-cd33 car-t cell therapy, Dr. Liu Fang said: "the experimental results of CCAR in the treatment of refractory AML to date are encouraging, and demonstrate the potential of this new treatment as a bridge for stem cell transplantation, as a supplement to chemotherapy, or as a separate treatment for all.

    "recommended reading: summary of the 23rd European annual meeting on hematology: voices from China have attracted the attention of peers around the world Compound car appeared in ash, focusing on four hot biomedical fields, including tumor immunity, new antibodies, stem cell regenerative medicine, and gene therapy. The 2020 bpit biopharmaceutical innovation technology conference will be held in Nanjing International Youth Culture Center, China, on July 19-21, 2020! Click the picture above to view the agenda of the conference
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.